We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KBC:EURONEXT BRUSSELSKBC Group N.V. Analysis

Data as of 2026-06-22 - not real-time

SEK 43.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

KB Components trades at 43.9 SEK, comfortably above its 20‑day (42.3), 50‑day (43.0) and 200‑day (42.5) moving averages, suggesting short‑term momentum despite a neutral trend direction. The RSI of 53.9 confirms the lack of extreme overbought or oversold pressure, while a bullish MACD crossover (histogram +0.03) adds a modest upside bias. However, volume is declining and 30‑day volatility is elevated at 86 %, and the stock’s beta of -0.54 indicates an inverse correlation to the broader market, which could amplify swings in a risk‑off environment.
Fundamentally, the company faces headwinds: revenue has fallen 12.5 % YoY, profit margins are thin (2.6 %), and the balance sheet is heavily leveraged with a debt‑to‑equity ratio over 200 %. While the trailing P/E of 35× appears stretched, the forward P/E of 12.4× hints at potential earnings recovery, yet the dividend yield of 3.9 % is unsustainable given a payout ratio above 120 % and modest free cash flow of only ≈37 M SEK. The market’s “Extreme Greed” sentiment (fear‑greed index 90.3) and a modest upside target of ≈7 % must be weighed against the high leverage and declining top line.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above all major moving averages
  • Bullish MACD signal
  • High volatility and decreasing volume

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Forward P/E suggests earnings upside
  • Target price implies ~7% upside
  • Attractive dividend yield despite sustainability concerns

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Elevated debt‑to‑equity ratio
  • Revenue contraction and thin profit margins
  • Uncertain dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth-12.50%
Profit Margin2.60%
P/E Ratio35.1
ROE10.97%
ROA4.00%
Debt/Equity202.41
P/B Ratio4.2
Op. Cash FlowSEK282.7M
Free Cash FlowSEK37.3M

Technical Analysis

TrendNeutral
RSI53.9
SupportSEK 38.40
ResistanceSEK 45.90
MA 20SEK 42.29
MA 50SEK 43.03
MA 200SEK 42.52
MACDBullish
VolumeDecreasing
Fear & Greed Index90.3

Valuation

Target PriceSEK 47.00
Upside/Downside7.06%
GradeOvervalued
TypeValue
Dividend Yield3.91%

Risk Assessment

Beta-0.54
Volatility86.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.